Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.
Julie Graff, MD
Advertisement
Articles by Julie Graff, MD
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Dr. Graff Discusses Sipuleucel-T in Patients With mCRPCPublished: December 8th 2017 | Updated:
Dr. Graff on the Role of Checkpoint Inhibitors in Prostate CancerPublished: December 27th 2017 | Updated:
Dr. Graff Discusses the Treatment of Prostate CancerPublished: January 9th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
5